Myc and E2F1 can each stimulate proliferation, induce apoptosis, and contribute to oncogenic transformation. However, only E2F1 has been shown to have a tumor suppressive activity under some conditions. To examine the potential of Myc to suppress tumorigenesis under one of the conditions in which E2F1 functions to suppress tumorigenesis, transgenic mice expressing Myc under the control of a keratin 5 (K5) promoter were generated. Like K5 E2F1 transgenic mice, K5 Myc transgenic mice have hyperplastic and hyperproliferative epidermis and develop spontaneous tumors in the skin and oral epithelium. In addition, K5 Myc and K5 E2F1 transgenic mice both display aberrant, p53-dependent apoptosis in the epidermis. It has been demonstrated that deregulated expression of E2F1 in the epidermis of transgenic mice inhibits tumorigenesis in a two-stage skin carcinogenesis assay. In sharp contrast to those results, deregulated expression of Myc in the epidermis of transgenic mice resulted in an enhanced response to two-stage skin carcinogenesis. We conclude that while Myc and E2F1 have similar proliferative, apoptotic and oncogenic properties in mouse epidermis, Myc lacks E2F1's tumor suppressive property. This suggests that E2F1's unique ability to inhibit skin carcinogenesis is not simply a consequence of promoting p53-dependent apoptosis. Oncogene (2001) 20, 5341 ± 5349.
Introduction
The Myc and E2F1 transcription factors have many properties in common. Both have been implicated in regulating the expression of genes crucial for cell cycle progression (Coller et al., 2000; DeGregori et al., 1995) . In fact, Myc and E2F1 (as well as some other members of these families) are the only mammalian transcription factors that can drive quiescent cells into the S phase of the cell cycle in the absence of other mitogenic signals (Johnson et al., 1993; Kaczmarek et al., 1985) . Both Myc and E2F1 are also potent inducers of apoptosis and, in many systems, their ability to induce apoptosis is largely dependent on the function of the p53 tumor suppressor protein (Hermeking and Eick, 1994; Kowalik et al., 1998; Sakamuro et al., 1995; Wu and Levine, 1994) . Like Myc, E2F1 can oncogenically transform immortalized rodent cells or cooperate with ras to transform primary rodent cells in culture (Johnson et al., 1994; Singh et al., 1994; Xu et al., 1995) . Moreover, it has recently been shown that deregulated expression of E2F1, like Myc, can induce spontaneous tumors in transgenic mice (Conner et al., 2000; Pierce et al., 1999) . There is evidence that Myc and E2F1 can regulate each other's expression (Hiebert et al., 1989; Leone et al., 1997) . However, it is unclear if Myc and E2F1 play a role in mediating each other's activities.
In addition to its oncogenic activity, E2F1 also has a tumor suppressive activity (Johnson, 2000) . This was ®rst demonstrated through the generation and characterization of mice lacking a functional E2f1 allele. E2f1 knockout mice are predisposed to developing a variety of tumors as they age including reproductive tract sarcomas and lymphomas (Yamasaki et al., 1996) . Further demonstration of E2F1's tumor suppressive activity comes from the ®nding that overexpression of E2F1 inhibits the growth of a variety of tumor cells in vitro and in nude mice (Fueyo et al., 1998; Hunt et al., 1997) . In addition, transgenic mice expressing E2F1 in the epidermis via a keratin 5 (K5) promoter develop much fewer skin tumors than nontransgenic mice in a two-stage chemical carcinogenesis assay . This is not the case for transgenic mice expressing related factors, such as E2F4, in the epidermis (Wang et al., 2000b) . It has been assumed that the ability of E2F1 to suppress tumor development in these models is related to E2F1's ability to induce apoptosis. In contrast to E2F1, a tumor suppressive activity has not been demonstrated for Myc despite the fact that Myc is also a potent inducer of apoptosis.
In this study, transgenic mice expressing Myc under the control of the K5 promoter are characterized. As expected, K5 Myc transgenic mice have a phenotype that is very similar to the phenotype of K5 E2F1 transgenic mice. Like K5 E2F1 transgenic mice (Pierce et al., 1998a,b) , K5 Myc transgenic mice have hyperplasia, hyperproliferation and aberrant, p53-dependent apoptosis in the epidermis. K5 Myc transgenic mice also develop spontaneous tumors in the skin and oral epithelium, the same tissues in which the majority of spontaneous tumors develop in K5 E2F1 transgenic mice . To determine if deregulated expression of Myc, like E2F1, could suppress tumor development in the twostage skin carcinogenesis assay, K5 Myc transgenic mice were treated with DMBA followed by repetitive treatments with TPA. In sharp contrast to K5 E2F1 transgenic mice, K5 Myc transgenic mice developed as many, if not more tumors as nontransgenic mice did following carcinogen treatment. Thus, Myc lacks E2F1's tumor suppressive activity in this model system.
Results

Development of K5 Myc transgenic mice
A K5 Myc transgene was generated by subcloning a murine c-myc genomic fragment containing exon 2 and exon 3, which includes the entire Myc protein coding region, into a vector containing the bovine K5 promoter, the rabbit b-globin intron 2, and the SV40 polyadenylation signal (Figure 1a ). The K5 promoter directs expression to the basal cell layer of the epidermis, the outer root sheath of hair follicles, and several other epithelial tissues (Ramirez et al., 1994) . Three K5 Myc transgenic lines (MM1, MM3, and MM5) were established from ®ve original founders. To determine the level of c-myc overexpression in the three lines, primary keratinocytes were cultured from newborn transgenic and wild type sibling pups from each line. Northern blot analysis was performed using RNA isolated from these primary keratinocyte cultures and a murine c-myc probe. Keratinocytes from the three transgenic lines overexpress c-myc to varying degrees as compared to wild type keratinocytes ( Figure 1b) . The level of c-myc overexpression for each line is 3.7-fold for MM1, 6.0-fold for MM3, and 2.8-fold for MM5.
To determine if K5 Myc transgenic mice have increased Myc activity in their epidermis, the expression levels of two well-characterized Myc target genes were examined. The ornithine decarboxylase (ODC) and cyclin D2 genes have each been shown to be transcriptional activated through functional Myc binding sites in their regulatory regions (BelloFernandez et al., 1993; Bouchard et al., 1999; Pena et al., 1993; Wagner et al., 1993) . Northern blot analysis of epidermal RNA demonstrated a fourfold induction of ODC and sixfold induction of cyclin D2 in K5 Myc transgenic mice compared to nontransgenic mice ( Figure 1c ). The expression of ODC and cyclin D2 was also increased in K5 E2F1 transgenic mice suggesting that these genes may also be targets of E2F1. Alternatively, E2F1 may indirectly induce ODC and cyclin D2 gene expression by stimulating endogenous Myc activity. However, previous analysis has demonstrated that c-myc mRNA levels are not signi®cantly upregulated (less than 1.5-fold) in K5 E2F1 transgenic mice (Wang et al., , 2000a ).
Proliferation and p53-dependent apoptosis in K5 Myc epidermis
Skin samples were taken from transgenic mice from the lines expressing the highest (MM3) and lowest (MM5) levels of the K5 Myc transgene to analyse epidermal hyperplasia, proliferation, and apoptosis. The average epidermal thickness of line MM3 mice was almost twice that observed in skin from wild type sibling mice (Figures 2 and 3a) . Mice from line MM5 demonstrated a lower level of epidermal hyperplasia. The level of hyperplasia correlated with the per cent of interfollicular basal keratinocytes in S phase as measured by BrdU incorporation (Figure 3b) . While approximately 2% of basal epidermal cells are in S phase in nontransgenic mice, this was increased to almost 15% in line MM3 mice and to 6% in line MM5 mice. The level of apoptosis in the epidermis was also determined in these skin sections by performing the TUNEL assay. Line MM3 mice had a 10-fold induction and line MM5 mice had a ®vefold induction in apoptosis over the background level of apoptosis detected in nontransgenic mice.
For comparison, the epidermal thickness, proliferation index, and apoptotic index of the two K5 E2F1 transgenic mouse lines is also presented (Figure 3 ). Hyperplasia and hyperproliferation are comparable between the higher expressing K5 Myc and K5 E2F1 lines (MM3 and E2F1.0) and between the lowerexpressing K5 Myc and K5 E2F1 lines (MM5 and E2F1.1). On the other hand, Myc appears to be a more potent inducer of apoptosis than is E2F1 in mouse epidermis. The apoptotic indexes of both K5 E2F1 transgenic lines are similar to or lower than the apoptotic index of the lower expressing MM5 line ( Figure 3c ).
In many systems the ability of Myc to induce apoptosis is largely dependent on the function of the p53 tumor suppressor protein (Hermeking and Eick, 1994; Sakamuro et al., 1995) . Apoptosis in K5 E2F1 transgenic mice has also been shown to be largely dependent on p53 (Pierce et al., 1998b) . To determine if Myc-induced apoptosis in transgenic epidermis is dependent on p53, K5 Myc transgenic mice were crossed into a p53 null background. In the absence of functional p53, apoptosis was reduced ®vefold in the MM5 transgenic line as measured by the TUNEL assay ( Figure 4b ). As an alternative method for detecting apoptotic cells, immunohistochemistry was performed on skin sections using an antibody that detects the activated form of caspase 3. This assay has a reduced background level compared to the TUNEL assay but may not be as sensitive at detecting apoptotic cells. Caspase 3-positive cells were detected only in K5 Myc transgenic epidermis that contained functional p53 ( Figure 4c ). Similar decreases in apoptosis were observed when other K5 Myc lines were crossed into a p53 null background (data not shown). In contrast, the proliferation index of K5 Myc mice was not signi®cantly aected by the status of p53 (Figure 4a ).
Thus, as with E2F1-induced apoptosis in K5 E2F1 transgenic mice, Myc-induced apoptosis in K5 Myc transgenic mice is largely dependent on functional p53.
Spontaneous tumor development in K5 Myc transgenic mice
To determine if deregulated expression of Myc could induce tumors in K5-expressing tissues, a group of K5 Myc transgenic mice were maintained for over 1 year (Table 1) . Several K5 Myc transgenic mice, particularly in the higher-expressing MM3 line, developed severe dermatitis that necessitated their removal from the study. The majority of tumors in K5 Myc transgenic mice developed in the oral epithelium, which expresses K5 Ramirez et al., 1994) . Some of these oral tumors resembled ameloblastomas while others were squamous cell carcinomas of the oral mucosa. A number of the oral tumors were complex odontogenic tumors containing a mixture of cell types. Additional pathological characterization of the odontogenic tumors will be presented elsewhere. The rest of the tumors in the K5 Myc transgenic mice occurred in the skin and were either squamous cell carcinomas or papillomas.
The skin and oral epithelium are the same two tissues in which the majority of tumors develop in K5 E2F1 transgenic mice, although the relative distribution between the two tissues is reversed . Another dierence between the K5 Myc and K5 E2F1 transgenic mice is that spontaneous tumor development occurs earlier in K5 Myc transgenic mice. Two founder K5 Myc transgenic mice, from which we were unable to establish lines, developed tumors at 20 and 22 weeks of age. Many of the tumors in the established lines also developed before 1 year of age. Tumors in K5 E2F1 transgenic mice usually develop after one year of age .
Impairment of p53 function can enhance Myc's tumorigenic potential (Elson et al., 1995; McCormack et al., 1998) . We previously demonstrated that K5 E2F1 transgenic mice have accelerated tumor formation in a p53 heterozygous background (Pierce et al., 1998b) . As a further comparison between the behavior of K5 Myc and K5 E2F1 transgenic mice, a group of 14 K5 Myc transgenic mice (line MM5) heterozygous for p53 were maintained and monitored for spontaneous tumor formation. These mice all developed tumors by 41 weeks of age ( Figure 5 ). Thirteen of these tumors were in K5-expressing tissues (skin and odontogenic epithelium) while one was a sarcoma. Control p53 heterozygous mice lacking the K5 Myc transgene (n=18) did not develop tumors in K5-expressing tissues but a few developed sarcomas or lymphomas by 1 year of age. In contrast to K5 Myc transgenic mice heterozygous for p53, less than 50% of K5 Myc transgenic mice wild type for p53 developed tumors by 41 weeks of age ( Figure 5 ). All tumors in transgenic mice with wild type p53 were in K5-expressing tissues. Thus, reduced p53 gene dosage accelerates both Myc-induced and E2F1-induced tumorigenesis in the K5 transgenic model system.
K5 Myc transgenic mice are sensitive to two-stage carcinogenesis
Our previous studies demonstrated that K5 E2F1 transgenic mice are resistant to developing tumors when used in a two-stage skin carcinogenesis assay that involves initiation with DMBA followed by repetitive . While nontransgenic sibling controls developed over 10 papillomas per mouse, K5 E2F1 transgenic mice developed less than one papilloma per mouse. If suppression of tumorigenesis in this model system is related to an increased propensity of K5 E2F1 transgenic cells to undergo apoptosis, we reasoned that K5 Myc transgenic mice, which also have increased apoptosis in the epidermis, might also be resistant to carcinogen treatment. To test this hypothesis, K5 Myc transgenic mice were used in the twostage skin carcinogenesis assay.
For this experiment, K5 Myc transgenic mice (line MM5) were backcrossed for ®ve generations into the SENCAR (Sensitive to Carcinogensis) inbred strain SSIN, as was previously done for K5 E2F1 transgenic mice. The dorsal skin of 6-week old mice was shaved and 2 days later mice were topically treated with DMBA. DMBA has been shown to initiate carcinogenesis by inducing an activating mutation in the endogenous murine c-Ha-ras gene. Two weeks after DMBA treatment, mice were topically treated with TPA twice per week to promote the growth of papillomas. Papillomas are benign, exophytic tumors that can progress to malignant squamous cell carcinomas over time. In contrast to what had been observed for K5 E2F1 transgenic mice, K5 Myc transgenic mice developed numerous papillomas following DMBA-TPA treatment (Figure 6a ). In fact, compared to nontransgenic sibling mice, K5 Myc transgenic mice appeared to develop tumors a little earlier and at the end of 20 weeks of promotion had a few more papillomas per mouse on average. Furthermore, the papillomas from K5 Myc transgenic mice were on average almost three times larger than the papillomas from nontransgenic controls (Figure 6b ). Overexpression of Myc also appeared to promote the conversion of papillomas to squamous cell carcinomas. Three out of 12 (25%) K5 Myc transgenic mice developed SCC by 20 weeks of promotion while conversion was not observed in the nontransgenic population.
Discussion
The mouse skin model is one of the most widely used in vivo models for studying the molecular and cellular biology of cancer. A variety of reproducible carcinogenesis assays have been developed for mouse skin. The two-stage carcinogenesis assay in particular has for over 50 years provided a framework from which to study the multistage nature of cancer development (Conti, 1994; DiGiovanni, 1994) . Furthermore, a variety of transgenic promoters have now been developed that target expression to mouse skin. The K5 promoter is expressed in the basal layer of the epidermis and the outer root sheath of the hair follicles (Ramirez et al., 1994) . This allows the targeted expression of speci®c factors, like Myc, to the compartment containing the epidermal stem cell population and the cells from which most skin cancers arise. Since most human tumors are epithelial in origin and since skin tumors are the most common of all human tumors, the mouse skin model is highly relevant to human cancer. Consistent with previous studies of Myc's biological activities, expression of Myc under the control of the K5 promoter resulted in increased proliferation and p53-dependent apoptosis in mouse epidermis. K5 Myc transgenic mice were also predisposed to developing spontaneous tumors, again consistent with previous transgenic models expressing Myc in other tissues (Adams et al., 1985; Schmidt et al., 1988; Stewart et al., 1984) . In the transgenic line expressing the lowest level of Myc (line MM5), spontaneous tumors developed at approximately 48 weeks of age on average. In the other lines, tumorigenesis occurred earlier. Tumor formation was also accelerated in a p53 heterozygous background. Tumors in the K5 Myc transgenic mice occurred in the oral epithelium and skin, but not in other K5-expressing tissues such as the bladder, thymus, or prostate. Given that the c-myc gene is commonly ampli®ed in human head and neck tumors (Field et al., 1989; Merritt et al., 1990) , K5 Myc transgenic mice may be a good model for this type of cancer.
Two recent studies also describe transgenic mouse models in which the expression of Myc was targeted to the skin. In one study, an inducible Myc fusion protein (MycER TM ) was targeted to the suprabasal layer of the epidermis via an involucrin (INV) promoter (Pelengaris et al., 1999) . In another study, Myc was placed under the control of the mouse loricrin (ML) promoter, which also targets expression to the suprabasal layer of the epidermis (Waikel et al., 1999) . Similar to our K5 Myc transgenic mice, induction of Myc in INVMycER TM transgenic mice resulted in activation of ODC, increased proliferation, and spontaneous papilloma development. ML.myc2 transgenic mice also had increased proliferation and hyperplasia in the epidermis. In contrast to K5 Myc transgenic mice however, neither of the transgenic models in which Myc was targeted to the suprabasal layer of the epidermis demonstrated increased apoptosis. In fact, ML.myc2 transgenic mice appeared to be more resistant to apoptosis following UV-B treatment (Waikel et al., 1999) . These ®ndings suggest that there is a dierence in the sensitivity to Myc-induced apoptosis between basal and suprabasal keratinocytes.
A major advantage of the mouse skin system is that it allows the simultaneous quantitative analysis of proliferation, apoptosis, and tumorigenesis all in the same primary epithelial tissue. This allows direct relationships to be established between alterations in proliferation or apoptosis and eects on tumor development. Table 2 presents a comparison among the abilities of E2F1, E2F4, and Myc to stimulate proliferation, induce apoptosis, promote spontaneous tumorigenesis, and suppress two-stage skin carcinogenesis in the K5 transgenic model system. Contrary to our expectations, the ability to suppress carcinogenesis does not strictly correlate with the ability to induce p53-dependent apoptosis. The apoptotic index of K5 Myc transgenic mice (line MM5) is similar to, if not higher than, the apoptotic index of K5 E2F1 transgenic mice, but only K5 E2F1 transgenic mice are refractory to two-stage skin carcinogenesis. This suggests that promotion of apoptosis through the stimulation of p53 activity may not be the mechanism by which E2F1 suppresses skin carcinogenesis. Alternatively, there may be a qualitative dierence between E2F1-induced apoptosis and Myc-induced apoptosis in this model system that results in resistance to carcinogenesis only K5 E2F1 transgenic mice.
In addition to apoptosis, there are several other possible mechanisms by which deregulated expression of E2F1 could suppress skin carcinogenesis. One possibility is that increased E2F1 activity, but not increased Myc activity, eects an aspect of keratinocyte dierentiation that modulates tumorigenesis. We have observed no obvious defect in the expression of epidermal dierentiation markers in K5 E2F1 or K5 Myc transgenic mice (Pierce et al., 1998a) , data not shown). However, staining for dierentiation markers is not quantitative and cannot measure changes in the rate of dierentiation. Angiogenesis is another aspect of carcinogenesis that could be inhibited by elevated levels of E2F1 but not Myc. These and other potential mechanisms of tumor suppression by E2F1 will be examined in future studies using the K5 transgenic model system. Instead of being resistant to two-stage skin carcinogenesis, K5 Myc transgenic mice appear to be more sensitive to this treatment. K5 Myc transgenic mice develop slightly more papillomas than nontransgenic controls and the papillomas that develop on the K5 Myc transgenic mice are signi®cantly larger than papillomas from nontransgenic mice. Moreover, expression of the K5 Myc transgene appears to stimulate the conversion of papillomas to SCC. This suggests that increased Myc activity may contribute to papilloma growth and conversion in the two-stage carcinogenesis assay. Further support of the idea that Myc plays a role in two-stage skin carcinogenesis comes from our previous demonstration that endogenous Myc expression is rapidly induced in the epidermis by treatment of nontransgenic mouse skin with the tumor promoter TPA (Rodriguez-Puebla et al., 1998) . Our ®nding that Myc is purely oncogenic in mouse epidermis while E2F1 has both oncogenic and tumor suppressive properties may help explain why the expression of Myc, but not E2F1, is often deregulated in human cancers.
As seen in Table 2 , there is not a strict correlation between the ability to stimulate proliferation and the ability to induce spontaneous tumors in the K5 transgenic models. Instead, there is a correlation between the ability to induce apoptosis and spontaneous tumorigenesis. K5 E2F4 transgenic mice lack increased epidermal apoptosis and do not develop spontaneous tumors despite having hyperproliferative and hyperplastic epidermis (Wang et al., 2000b) . In fact, K5 E2F4 transgenic epidermis is more hyperplastic than either K5 E2F1 or K5 Myc epidermis. This ®nding may at ®rst appear to be counter-intuitive. It might be expected that a factor that induces proliferation but not apoptosis would be more oncogenic than factors that induce both proliferation and apoptosis. Yet this is not the case.
One possible explanation for these correlations is that E2F1 and Myc stimulate proliferation in a way that promotes tumorigenesis while E2F4 induces proliferation through a non-oncogenic pathway. It may be that p53-dependent apoptosis is triggered only when an oncogenic proliferative pathway is engaged. In support of the idea that E2F1 and E2F4 induce proliferation through dierent mechanisms, we have shown that the expression of cyclin E is upregulated only in E2F1 transgenic cells and not in E2F4 transgenic cells (Wang et al., 2000b) .
Another possibility is that the ability to induce p53-dependent apoptosis is an important aspect of the tumorigenic potential of factors like E2F1 and Myc, perhaps by creating a selective pressure for mutations that impair p53 function. Of course other activities of E2F1 and Myc, such as eects on genetic stability, angiogenesis and dierentiation, may also contribute to the tumorigenic properties of E2F1 and Myc.
Materials and methods
Transgenic mice
The K5 Myc transgene was made by cloning a murine c-myc genomic fragment containing exon 2 and exon 3 (a kind gift from Dr Andrew Butler) into a plasmid (BSK5) containing the bovine K5 promoter (Ramirez et al., 1994) , the rabbit bglobin intron 2, and the simian virus 40 polyadenylation signal. Founder transgenic mice were made by microinjecting the puri®ed transgene into the pronuclei of zygotes and then implanting the zygotes into pseudo-pregnant female mice. Lines were established and maintained by backcrossing the founders to the SENCAR inbred strain SSIN.
Northern blot analyses
Northern blot analyses were performed using RNA isolated from primary keratinocytes for determining c-myc expression or using RNA isolated from scrapes of the dorsal epidermis of adult mice for ODC, cyclin D2, and 7S analyses. Primary keratinocytes were isolated from newborn mice by incubating washed skins in 0.25% trypsin/phosphate-buered saline (PBS) overnight at 48C. Epidermis was then separated from the dermis, minced in culture media, and stirred for 20 min. The cell suspension was ®ltered through nylon mesh, cells counted, and plated at a density of 3 million/35 mm dish. Media was changed after 2 h and harvested after 48 h. Total RNA was isolated with Tri-Reagent (Molecular Research Center, Inc.) by the manufacturer's protocol. A murine c-myc fragment containing exons 2 and 3 was labeled and used as probe. Murine cDNA probes were kind gifts from Dr Andrew Butler (ODC) and Dr Charles Sherr (cyclin D2).
BrdU incorporation
Mice were injected with 170 ml of 20 mM bromodeoxyuridine (BrdU), allowed to incorporate for 20 min, and sacri®ced. Skin samples were collected, ®xed in formalin, and paranembedded. Tissue sections were then deparanized and ®xed in methanol containing 1% hydrogen peroxide for 20 min. Tissue sections were rinsed with PBS containing 0.1% BSA three times for 5 min each. Slides were preincubated with normal goat serum for 20 min before addition of primary BrdU antibody (1 : 500, Becton Dickinson). Sections were incubated for 30 min, rinsed with PBS/BSA, and then incubated with biotinylated anti-rabbit IgG for 30 min. Slides were rinsed with PBS/BSA and developed with streptavidenhorseradish peroxidase conjugate and diaminobenzidine (DAB) substrate. Tissue sections were rinsed again and counterstained before mounting. For determining per cent incorporation, interfollicular basal cells were examined, and the number of unstained and stained cells was determined. At least 1000 cells were counted per section.
Apoptosis assay
Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assays were performed in formalin-®xed, paran-embedded skin sections using an ApopTag in situ apoptosis detection kit (Oncor). TUNELpositive epidermal keratinocytes were visualized by peroxidase-diaminobenzidine staining. For activated caspase 3 staining, formalin-®xed, paran-embedded skin sections were deparanized and ®xed using methanol with 3% hydrogen peroxide for 20 min. Slides were rinsed in PBS three times for 3 min each before immunohistochemistry preparation and development with Histostain-Plus kit (Zymed) and anticaspase 3 antibody (R&D Systems, 1 : 2000 dilution). Tissues were rinsed with H 2 O and counterstained before being mounted.
Mouse two-stage carcinogenesis assay
Tumors were initiated on 6-week old mice by topical application of 10 nmol of 9,10-dimethyl-1,2-benzanthracene (DMBA) in 200 ml of acetone to previously shaved dorsal skin. Tumors were promoted twice weekly by topical application of 1.0 mg of 12-O-tetradecanoylphorbol-13-acetate (TPA) in 200 ml of acetone beginning 2 weeks after initiation. Mice were scored for palpable papillomas weekly.
